These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35977549)

  • 1. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.
    Bardaweel S; Issa A
    J Pharm Pharm Sci; 2022; 25():253-265. PubMed ID: 35977549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sodium-Glucose Co-Transporter 2 Inhibitors Combined with Metformin on Pancreatic Cancer Cell Lines.
    Cristovão A; Andrade N; Martel F; Silva C
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
    Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
    Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
    Komatsu S; Nomiyama T; Numata T; Kawanami T; Hamaguchi Y; Iwaya C; Horikawa T; Fujimura-Tanaka Y; Hamanoue N; Motonaga R; Tanabe M; Inoue R; Yanase T; Kawanami D
    Endocr J; 2020 Jan; 67(1):99-106. PubMed ID: 31776304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
    Sakaeda T; Kobuchi S; Yoshioka R; Haruna M; Takahata N; Ito Y; Sugano A; Fukuzawa K; Hayase T; Hayakawa T; Nakayama H; Takaoka Y; Tohkin M
    Int J Med Sci; 2018; 15(9):937-943. PubMed ID: 30008607
    [No Abstract]   [Full Text] [Related]  

  • 7. High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.
    Umino H; Hasegawa K; Minakuchi H; Muraoka H; Kawaguchi T; Kanda T; Tokuyama H; Wakino S; Itoh H
    Sci Rep; 2018 May; 8(1):6791. PubMed ID: 29717156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
    Shoda K; Tsuji S; Nakamura S; Egashira Y; Enomoto Y; Nakayama N; Shimazawa M; Iwama T; Hara H
    Cell Mol Neurobiol; 2023 Mar; 43(2):879-892. PubMed ID: 35435536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
    Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
    Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus.
    Davis CS; Fleming JW; Warrington LE
    J Am Assoc Nurse Pract; 2014 Jul; 26(7):356-63. PubMed ID: 24895099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [
    van der Hoek S; Willemsen ATM; Visser T; Heeres A; Mulder DJ; Bokkers RPH; Slart RHJA; Elsinga PH; Heerspink HJL; Stevens J
    Clin Pharmacol Ther; 2023 Jun; 113(6):1295-1303. PubMed ID: 36897753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy.
    Herat LY; Matthews JR; Rakoczy EP; Schlaich MP; Matthews VB
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):83. PubMed ID: 37114550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells.
    Anastasio C; Donisi I; Del Vecchio V; Colloca A; Mele L; Sardu C; Marfella R; Balestrieri ML; D'Onofrio N
    Cell Mol Biol Lett; 2024 May; 29(1):80. PubMed ID: 38811901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.